U.S. biotech developer Edgewise Therapeutics has entered into a definitive agreement to sell its muscular dystrophy drug candidate and related business assets to the French pharmaceutical group Servier in a transaction valued at up to $2.65 billion. The blockbuster acquisition represents a targeted structural expansion for Servier beyond its traditional, core therapeutic pillars of oncology and cardiovascular disease. Under the signed financial terms, Edgewise will capture an upfront cash payment of $1.55 billion in exchange for the total global rights to its experimental drug, sevasemten. The American biotech remains supplementary eligible to secure up to $1.1 billion in conditional development, regulatory, and commercial milestone tranches.
The underlying clinical metrics, product portfolio profiling, and strategic capital reallocations executed by both entities include:
-
Clinical Efficacy Profile of Sevasemten: Sevasemten is an investigational targeted therapeutic designed to treat both Becker and Duchenne muscular dystrophy. In early-stage clinical trial cohorts, the small molecule demonstrated measurable benefits in muscle function among Becker patients, generated significant reductions in validated muscle damage biomarkers, and tracked a favorable safety index. While the Becker landscape currently features zero approved therapeutic options, the Duchenne market contains several authorized products, including Sarepta Therapeutics’ breakthrough gene therapy, Elevidys.
-
Servier’s Rare Disease Core Pivot: This transaction materializes nearly three months after Servier finalized a $2.5 billion acquisition of Day One Biopharma to scale up its neuro-oncology footprint. Servier CEO David Lee noted that the acquisition configures a “three legs to the stool type approach” required to systematically enter the neurology arena. He emphasized that the United States represents the primary strategic growth engine fueling Servier’s long-term corporate pivot into rare diseases. Pivotal late-stage data readouts for sevasemten remain on track for release in the fourth quarter of this year, and Servier intends to leverage the data to pursue an accelerated regulatory approval pathway.
-
Resource Optimization for Edgewise: For Edgewise Therapeutics, the definitive asset divestiture successfully removes a primary operational overhang, allowing management to optimize its clinical focus on its frontline cardiovascular program, EDG-7500, while heavily fortifying its corporate balance sheet. Crucial 12-week data pulled from the heart drug’s mid-stage Phase II trial is projected for publication within the current second quarter. The transaction is legally expected to close within the third quarter of this year.
-
Wall Street Projections and Equity Performance: Truist financial analyst Srikripa Devarakonda models peak global sales for sevasemten within the Becker indication alone to reach up to $1.04 billion. Following the corporate announcement, shares of the U.S.-listed Edgewise Therapeutics surged by as much as 14.3% in intraday trading, reaching an all-time historical high of $40.8 per share.